I think we are in agreement on FDA putting the cart before the horse on safety vs whatever efficacy there is/might be with regard to the slew of quick approvals of ICIs.
Be that as it may, patients are now faced with the issue wading through the known data and making a choice to use a particular ICI if it is available for their cancer. Unfortunately many will go along with their onc’s recommendation in the absence of a meaningful conversation about the patient’s risk/reward tolerance or other relevant health priorities, etc.
News 
Market Data 
Discover 
